The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Previous

Tenofovir for Hepatitis B Suppression

Back to News Homepage

Next

An Overview of Autoimmune Hepatitis

Report Shows Triple Therapy is New Hep C Standard

December 28, 2011

Print this page

Six months after Incivek and Victrelis were approved by the FDA for Hepatitis C, a LaunchTrends® report indicates that triple therapy with these drugs is the new standard of care for treating genotype 1 Hepatitis C.

Incivek and Victrelis Usage as Part of Triple Therapy Hepatitis C Regimen is Emerging as the New Standard of Care for Genotype 1 Patients According to a Newly Released Report by BioTrends Research Group

By Benzinga Staff

December 22, 2011

Six months post-launch of Vertex’s Incivek (telapravir) and Merck/Roche’s Victrelis (boceprevir), specialists report a significant increase in usage of both products in their genotype 1 HCV patients compared to one month post-launch. Incivek remains the market share leader, though the gap in preference for Incivek over Victrelis is beginning to narrow compared to previous waves of research. Surveyed hepatologists reported using significantly more Incivek than infectious disease specialists.

In LaunchTrends®: Victrelis (boceprevir) and Incivek (telapravir) Wave 3 BioTrends surveyed a total of 83 physicians (gastroenterologists, hepatologists, and infectious disease specialists) and conducted in-depth qualitative interviews with a subset of the respondents about their current perceptions, early experience and anticipated future use of these products. In addition, feedback around patient type, product satisfaction, patient influence, obstacles to use, and promotional activities is captured.

Continue reading this entire article:

http://www.benzinga.com/pressreleases/11/12/b2226050/incivek-and-victrelis-usage-as-part-of-triple-therapy-hepatitis-c-regim

No Comments - be the first!
Share
Share

Previous

Tenofovir for Hepatitis B Suppression

Back to News Homepage

Next

An Overview of Autoimmune Hepatitis

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.